NCT06680206Completed
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
Comparing Patient-Reported Outcomes Between Rimegepant and Triptan Users With Migraine in the United States
Source: ClinicalTrials.gov · Last updated 22 Jan 2026
Brief summary (registry, in English)
This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007). All data from the NHWS are reported by respondents, who are recruited through an existing, general-purpose, web-based, consumer panel via opt-in e-mails, co-registration with panel partners, e-newsletter campaigns, banner placements, and affiliate networks. All respondents explicitly agree to be a panel member, register with the panel through a unique e-mail address, and complete an in-depth demographic registration profile. This analysis will focus on respondents who self-report having migraine diagnosed by a physician. Individuals who use rimegepant for acute treatment of migraine will be compared with those who use triptans for acute treatment of migraine. Outcomes of interest include treatment satisfaction, healthcare resource utilization (HCRU), quality of life (QoL), work productivity loss, and migraine-specific disability outcomes. Inverse probability of treatment weighting (IPTW) will be used to adjust for differences that may exist between rimegepant and triptan users prior to comparing outcomes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1395 (actual)
- First submitted
- 21 Oct 2024
- Start date
- 10 Oct 2024
- Primary completion date
- 20 Nov 2024
- Lead sponsor
- Pfizer
- Diseases
- Migraine
- NCT number
- NCT06680206
What you commit to
- Study type: Observational
- Participants enrolled: 1395
- From 10 Oct 2024 to the primary completion date, 20 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Currently on both rimegepant and triptans at the time of the survey
Who the study is looking for
- Participated in 2023 NHWS in the US
- Consented to the anonymous use of their data for research purpose
- Aged 18 or older
- Self-reported a diagnosis of migraine by physician
- Currently on rimegepant or triptan (via oral route) at the time of the survey
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.